Jim Cramer says Eli Lilly should soon top a $1 trillion stock market value

Eli Lilly's stock is nearing a $1 trillion market capitalization, with shares surpassing $1,000 for the first time, driven by strong bullish sentiment surrounding its weight-loss drug pipeline. Analysts, including Jim Cramer and Citi, are particularly optimistic about the upcoming pill version of its GLP-1 treatment, orforglipron, expected in late 2026, which is anticipated to significantly boost sales given broader access through a recent White House deal for Medicare/Medicaid beneficiaries. Citi notably raised its 2026 pill sales forecast to $1.8 billion and increased Lilly's price target to $1,500, signaling accelerated market domination despite a prior setback from trial data.

Analysis

Eli Lilly (LLY) shares have demonstrated significant momentum, recently surpassing $1,000 for the first time and nearing a $1 trillion market capitalization, driven by strong investor confidence in its GLP-1 franchise. This surge follows a recent White House agreement that will broaden Medicare and Medicaid access to Lilly's obesity drugs, including Zepbound (tirzepatide), starting in 2026, enhancing market reach.

A key future catalyst is the anticipated launch of orforglipron, Lilly's oral GLP-1 treatment, in the second half of 2026, which is expected to unlock substantial sales growth due to patient preference for pills over injectables and easier manufacturing. Citi analysts have significantly raised their 2026 sales forecast for the pill to $1.8 billion from $500 million, concurrently increasing Lilly's price target to a Street-high $1,500, implying over 50% upside.

This robust bullish sentiment, echoed by figures like Jim Cramer, suggests an acceleration of Lilly's market domination in the GLP-1 category, despite a previous 14% stock decline in August due to unrelated late-stage trial data. The combination of regulatory tailwinds and a promising product pipeline positions Lilly for continued growth and potential to become the first pharmaceutical company to reach a $1 trillion valuation.

Key Decisions for Investors

• Investors should assess Eli Lilly's long-term growth trajectory, driven by the anticipated launch of its oral GLP-1 treatment, orforglipron, and expanded market access through the White House deal.
• Closely monitor the progress and regulatory milestones for orforglipron, as well as any competitive developments in the rapidly evolving GLP-1 market, which are crucial for sustaining current valuation premiums.
• While analyst sentiment is highly bullish with significant upside targets, investors should consider the stock's sensitivity to clinical trial outcomes and regulatory news, maintaining a balanced risk perspective.